Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma

Journal of Clinical Oncology

Volumn 25, Issue 21, 2007, Pages 3109-3115

  Olsen, Elise A ^a   Kim, Youn H ^a   Kuzel, Timothy M ^a   Pacheco, Theresa R ^a   Foss, Francine M ^a   Parker, Sareeta ^a   Frankel, Stanley R ^a   Chen, Cong ^a   Ricker, Justin L ^a   Arduino, Jean Marie ^a   Duvic, Madeleine ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; DENILEUKIN DIFTITOX; HISTONE DEACETYLASE INHIBITOR; PREDNISONE; TRIAMCINOLONE ACETONIDE; VORINOSTAT; WARFARIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BACTEREMIA; CEREBROVASCULAR ACCIDENT; CHILL; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; DEATH; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ECG ABNORMALITY; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; MYCOSIS FUNGOIDES; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; SEZARY SYNDROME; SIDE EFFECT; SYNCOPE; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; SALVAGE THERAPY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34547683194     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.2434     Document Type: Article

References (26)

1. de Coninck EC, Kim YH, Varghese A, et al: Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 19:779-784, 2001
2. Willemze R, Jaffe ES, Burg G, et al: WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005
3. Bunn PA Jr, Lamberg SI: Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 63:725-728, 1979
4. Kim YH, Willemze R, Pimpinelli N, et al: TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood [epub ahead of print on March 15, 2007]
5. Vonderheid EC, Bernengo MG, Burg G, et al: Update on erythrodermic cutaneous T-cell lymphoma: Report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46:95-106, 2002
6. Kim YH, Liu HL, Mraz-Gernhard S, et al: Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: Clinical prognostic factors and risk for disease progression. Arch Dermatol 139:857-866, 2003
7. Kelly WK, O'Connor OA, Krug LM, et al: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931, 2005
8. O'Connor OA: Developing new drugs for the treatment of lymphoma. Eur J Haematol 75:150-158, 2005 (suppl 66)
9. Marks P, Rifkind RA, Richon VM, et al: Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1:194-202, 2001
10. Timmermann S, Lehrmann H, Polesskaya A, et al: Histone acetylation and disease. Cell Mol Life Sci 58:728-736, 2001
11. Butler LM, Agus DB, Scher HI, et al: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170, 2000
12. Cohen LA, Marks PA, Rifkind RA, et al: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res 22:1497-1504, 2002
13. He LZ, Tolentino T, Grayson P, et al: Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 108:1321-1330, 2001
14. Zhang C, Richon V, Ni X, et al: Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. J Invest Dermatol 125:1045-1052, 2005
15. Garcia-Manero G, Yang H, Sanchez-Gonzalez B, et al: Final results of a phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with leukemia and myelodysplastic syndrome. Blood 106:785a, 2005
16. Kelly WK, Richon VM, O'Connor O, et al: Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578-3588, 2003
17. O'Connor OA, Heaney ML, Schwartz L, et al: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166-173, 2006
18. Rubin EH, Agrawal NG, Friedman EJ, et al: A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat administered orally to patients with advanced cancer. Clin Cancer Res 12:7039-7045, 2006
19. Duvic M, Talpur R, Ni X, et al: Phase II trial of oral vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) for refractory cutaneous t-cell lymphoma (CTCL). Blood 109:31-39, 2007
20. Duvic M, Hymes K, Heald P, et al: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol 19: 2456-2471, 2001
21. Ontak® (denileukin diftitox) product label details. http://www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN= denileukin%20difitox
22. Olsen E, Duvic M, Frankel A, et al: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376-388, 2001
23. Duvic M, Kuzel TM, Olsen EA, et al: Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clin Lymphoma 2:222-228, 2002
24. King LE Jr, Dufresne RG Jr, Lovett GL, et al: Erythroderma: Review of 82 cases. South Med J 79:1210-1215, 1986
25. Giles F, Fischer T, Cortes J, et al: A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12:4628-4635, 2006
26. Piekarz RL, Frye AR, Wright JJ, et al: Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 12:3762-3773, 2006